Tumor-induced osteomalacia: Lessons learned

Arthritis and Rheumatism

Volumn 58, Issue 3, 2008, Pages 773-777

  Lewiecki, E Michael ^a   Urig Jr , Edward J ^b   Williams Jr , Ralph C ^c  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b St Vincent's Hospital   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PHOSPHORUS; PREDNISONE; SALAZOSULFAPYRIDINE; TECHNETIUM; ZOLEDRONIC ACID;

ADULT; ARTICLE; BLOOD CHEMISTRY; BONE BIOPSY; BONE PAIN; CASE REPORT; DOWN REGULATION; FATIGUE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; HYPOPHOSPHATEMIA; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; LABORATORY TEST; MALE; METABOLIC DISORDER; MYALGIA; ONCOGENIC OSTEOMALACIA; OUTCOME ASSESSMENT; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL;

BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MANDIBULAR NEOPLASMS; MIDDLE AGED; OSTEOMALACIA; PHOSPHORUS; VITAMIN D;

EID: 40549109547     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23278     Document Type: Article

References (13)

1. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975;2:309-10.
2. Jan de Beur SM. Tumor-induced osteomalacia. In: Favus MJ, editor. Primer of the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington (DC): American Society for Bone and Mineral Research; 2006. p. 345-51.
3. Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002;359:761-3.
4. Jan de Beur SM. Tumor-induced osteomalacia. JAMA 2005;294:1260-7.
5. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 2000;27:333-8.
6. McCrance RA. Osteomalacia with Looser's nodes (milkman's syndrome) due to a raised resistance to vitamin D about the age of 15 years. Q J Med 1947;16:33-46.
7. Prader A, Illig R, Uehlinger E, Stalder G. [Rickets following bone tumor.] Helv Pediatr Acta 1959;14:554-65. In German.
8. Jan de Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002;17:1102-10.
9. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000;67:54-68.
10. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004;34:303-19.
11. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004;314:409-14.
12. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284:977-81.
13. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1-30.